These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1755921)

  • 21. Modification of Grimont biotyping system for epidemiologic studies with nosocomial Serratia marcescens isolates.
    Sifuentes-Osornio J; Gröschel DH
    J Clin Microbiol; 1987 Mar; 25(3):567-8. PubMed ID: 3553228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined serotyping and biotyping of Serratia marcescens.
    Rubin SJ; Brock S; Chamberland M; Lyons RW
    J Clin Microbiol; 1976 Jun; 3(6):582-5. PubMed ID: 780372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of methods for differentiating among Serratia marcescens isolated from clinical specimens.
    Roemisch E; Kocka FE
    Am J Clin Pathol; 1976 Jul; 66(1):96-100. PubMed ID: 779447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiological differentiation of Serratia marcescens: typing by bacteriocin production.
    Farmer JJ
    Appl Microbiol; 1972 Feb; 23(2):218-25. PubMed ID: 4552884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Typing of nosocomial strains of Serratia marcescens: comparison of pulsed-field gel electrophoresis of macrorestriction fragments with biotyping, esterase typing and ribotyping.
    Chetoui H; Delhalle E; Melin P; Struelens MJ; De Ryck R; Osterrieth P; De Mol P
    Res Microbiol; 1998 Feb; 149(2):137-43. PubMed ID: 9766216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacteriocin 28b, a chromosomally encoded bacteriocin produced by most Serratia marcescens biotypes.
    Guasch JF; Enfedaque J; Ferrer S; Gargallo D; Regué M
    Res Microbiol; 1995; 146(6):477-83. PubMed ID: 8525064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biotyping of Serratia marcescens and its use in epidemiological studies.
    Grimont PA; Grimont F
    J Clin Microbiol; 1978 Jul; 8(1):73-83. PubMed ID: 353073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme polymorphism, prodigiosin production, and plasmid fingerprints in clinical and naturally occurring isolates of Serratia marcescens.
    Gargallo-Viola D
    J Clin Microbiol; 1989 May; 27(5):860-8. PubMed ID: 2663918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of biotyping and electrophoretic patterns of esterases for differentiation of nosocomial Serratia marcescens strains.
    Chetoui H; Delhalle E; Osterrieth P; Rousseaux D
    Res Microbiol; 1995 Sep; 146(7):579-86. PubMed ID: 8577999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of typing methods for Serratia marcescens.
    Anderhub B; Pitt TL; Erdman YJ; Willcox WR
    J Hyg (Lond); 1977 Aug; 79(1):89-102. PubMed ID: 328770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study on bacteriocin (marcescin) typing of Serratia marcescens. I. Fundamental studies on bacteriocin (marcescin) production and sensitivity (author's transl)].
    Nasu M
    Kansenshogaku Zasshi; 1977 Sep; 51(9):487-98. PubMed ID: 416153
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of MALDI-TOF mass spectrometry to detect nosocomial outbreaks of Serratia marcescens and Citrobacter freundii.
    Rödel J; Mellmann A; Stein C; Alexi M; Kipp F; Edel B; Dawczynski K; Brandt C; Seidel L; Pfister W; Löffler B; Straube E
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):581-591. PubMed ID: 30680577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serratia marcescens.
    Hejazi A; Falkiner FR
    J Med Microbiol; 1997 Nov; 46(11):903-12. PubMed ID: 9368530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic variations of bacteriocin susceptibility, O-antigen determinants, and serum susceptibility among isolates of a multiple-drug-resistant, nosocomially significant strain of Serratia marcescens.
    Traub WH
    Zentralbl Bakteriol Orig A; 1978 Jan; 240(1):57-75. PubMed ID: 76383
    [No Abstract]   [Full Text] [Related]  

  • 35. [Serratia marcescens infections in a hospital: typing of isolated strains].
    Yde M
    Arch Belg; 1989; 47(5-6):189-210. PubMed ID: 2700064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on group A (phage tail) bacteriocins of Serratia marcescens. V. Serological characterization of subgroup I and II bacteriocins.
    Traub WH; Kleber I
    Zentralbl Bakteriol Orig A; 1976 May; 234(4):521-7. PubMed ID: 779357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A study on the epidemiology of Sarratia marcescens using bacteriocin typing].
    Fritsche D; Dostal C; Spieckermann C
    Zentralbl Bakteriol Orig A; 1973 May; 223(4):513-9. PubMed ID: 4146827
    [No Abstract]   [Full Text] [Related]  

  • 38. Bacteriophage typing of clinically isolated Serratia marcescens.
    Hamilton RL; Brown WJ
    Appl Microbiol; 1972 Dec; 24(6):899-906. PubMed ID: 4568252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance of Pseudomonas aeruginosa in intensive care units: clusters of nosocomial cross-infection and encounter of a multiple-antibiotic resistant strain.
    Traub WH; Scheidhauer R; Leonhard B; Bauer D
    Chemotherapy; 1998; 44(4):243-59. PubMed ID: 9681201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiological studies of Serratia marcescens infections by bacteriocin (marcescin) typing.
    Nasu M
    Tohoku J Exp Med; 1981 Jan; 133(1):45-52. PubMed ID: 7015561
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.